Reata Pharmaceuticals Prices Class A Common Stock Offering
Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million.
The offering priced on December 1, 2020 and is expected to close on or about December 4, 2020.
Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.
The V&E corporate team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associates Grace-Ann Duquette and Joseph Steuert. Advising on tax matters were partner Wendy Salinas and associate Liz Snyder.
About Vinson & Elkins
For more than 100 years, Vinson & Elkins has provided deep experience in handling transactions, investments, projects, and disputes worldwide. The firm is a trusted adviser to clients in the most important industrial and digital industries. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.
For more information, please speak with our media contacts.
Key Contacts
Related Insights
- Insight
Published in Bloomberg Law
June 21, 2021 - Insight
V&E American Jobs Plan Update
April 2, 2021 - Event RecapMarch 3, 2021Video
- Insight
UK Tax Update
February 1, 2021